logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
BackJournal Details
P

Pharmaceutical Statistics

IF1.4
Papers51
Citations
Journal Papers 51
Publication Date
delete
Diagnostic Accuracy Measures and Optimal Cut-Off Points for Nested Disease Subtypes Within the Disease Ordinal States
deletePharmaceutical Statistics
IF1.4
delete2026-05-01
delete0
PREAI
deleteSamawi, Hani; Alsharman, Marwan; Kersey, Jing
deleteShare
deleteSave
Evolving Variants, Shifting Outcomes: Implications for Nonconcurrent Controls in Platform Trials for COVID-19
deletePharmaceutical Statistics
IF1.4
delete2026-05-01
delete0
PREAI
deleteWatanabe, Shin; Shimizu, Yosuke; Sato, Hiroyuki; Uemura, Yukari; Hirakawa, Akihiro
deleteShare
deleteSave
A Constrained Hierarchical Bayesian Model Considering Latent Biomarker Subgroups for Time-To-Event Endpoints in Randomized Phase II Trials
deletePharmaceutical Statistics
IF1.4
delete2026-05-01
delete0
PREAI
deleteHuang, Yifei; Takeda, Kentaro; Zhao, Yongyun
deleteShare
deleteSave
A Seamless Two-Stage Phase I/II Trial Design With Backfill and Joint Monitoring for Dose Optimization
deletePharmaceutical Statistics
IF1.4
delete2026-05-01
delete1
PREAI
deleteTakeda, Kentaro; Zhu, Jing; Yimer, Belay B.; Hirakawa, Akihiro
deleteShare
deleteSave
Consistency Assessment and Regional Sample Size Calculation for MRCT Under Random Effects Model
deletePharmaceutical Statistics
IF1.4
delete2026-05-01
delete0
PREAI
deleteRen, Xinru; Xu, Jin
deleteShare
deleteSave
A Dose-Finding Design for Drug Combinations Using a Bayesian 4 Parameter Logistic Model With Penalised D-Optimality
deletePharmaceutical Statistics
IF1.4
delete2026-05-01
delete0
deleteOAAI
deleteAjimi, Maxine; Webb, Benjamin; Wheeler, Graham M.; Marshall, Jayne; Mander, Adrian P.
deleteShare
deleteSave
Phase III Probability of Success When Early Development Is Based on a Putative Surrogate Endpoint: A Vaccine Efficacy Case Study
deletePharmaceutical Statistics
IF1.4
delete2026-05-01
delete0
PREAI
deleteCallegaro, Andrea; Solmi, Francesca; Noirjean, Silvia; Conti, Valentino; Tibaldi, Fabian; Eletti, Alessia
deleteShare
deleteSave
RABOTS: A Randomized Adaptive Bayesian Optimization Two-Stage Seamless Design for Dose Optimization and Proof-of-Concept Evaluation
deletePharmaceutical Statistics
IF1.4
delete2026-05-01
delete0
PREAI
deleteZhu, Xiaochen; Li, Yiwei; Wu, Jiaju; Tang, Yike; Liu, Liangang; Huang, Shu-Pang; Hsieh, Hsin-Ju
deleteShare
deleteSave
Predictive Biomarker Graphical Approach (PRIME) for Precision Medicine
deletePharmaceutical Statistics
IF1.4
delete2026-05-01
delete0
PREAI
deleteD'Angelo, Gina; Tian, Xiaowen; Deng, Chuyu; Zhou, Xian
deleteShare
deleteSave
An Ensemble Classifier for Ordinal Outcomes in High-Dimensional Genomics Data
deletePharmaceutical Statistics
IF1.4
delete2026-05-01
delete0
PREAI
deleteRathnasekara, Heranga K.; Sikdar, Sinjini
deleteShare
deleteSave
Integrating Preclinical Insights for Adaptive Dose Escalation in Phase I Oncology Trials
deletePharmaceutical Statistics
IF1.4
delete2026-05-01
delete0
PREAI
deleteBarnett, Helen; Guhl, Melanie; Di Stefano, Fulvio; Skanji, Donia; Guilleminot, Sandrine; Saint-Hilary, Gaelle; Mozgunov, Pavel; Riviere, Marie-Karelle
deleteShare
deleteSave
Evaluating Safety Rules in Ongoing Dose-Escalation Trials Using BOIN: A Comparative Analysis of Criteria and Their Impact on Dose-Level Safety Assessments
deletePharmaceutical Statistics
IF1.4
delete2026-03-01
delete0
PREAI
deleteEnglert, Stefan; Prior, Thomas J.; Mitra, Anirban; Sanusi, Busola; Zhang, Liangcai; Di Scala, Lilla
deleteShare
deleteSave
Using Off-Treatment Sequential Multiple Imputation for Binary Outcomes to Address Intercurrent Events Handled by a Treatment Policy Strategy
deletePharmaceutical Statistics
IF1.4
delete2026-03-01
delete0
PREAI
deleteRehal, Sunita; Best, Nicky; Watts, Sarah; Drury, Thomas
deleteShare
deleteSave
Bayesian Power-Based Sample Size Determination for Single-Arm Clinical Trials With Time-to-Event Endpoints
deletePharmaceutical Statistics
IF1.4
delete2026-03-01
delete0
PREAI
deleteHoriguchi, Go; Yokota, Isao; Teramukai, Satoshi
deleteShare
deleteSave
Within-Trial Prognostic Score Adjustment Is Targeted Maximum Likelihood Estimation
deletePharmaceutical Statistics
IF1.4
delete2026-03-01
delete0
PREAI
deleteHojbjerre-Frandsen, Emilie; Schuler, Alejandro
deleteShare
deleteSave
Penalized Variable Selection for Joint AFT Random-Effect Model With Clustered Competing-Risks Data
deletePharmaceutical Statistics
IF1.4
delete2026-03-01
delete0
PREAI
deleteHao, Lin; Do Ha, Il
deleteShare
deleteSave
Methodological Approaches for the Estimation of Confidence Intervals on Partial Youden Index Under Verification Bias
deletePharmaceutical Statistics
IF1.4
delete2026-03-01
delete0
PREAI
deleteJia, Sihan; Wang, Shirui; Qin, Gengsheng
deleteShare
deleteSave
An Association Test for Ordinal Outcomes in Clustered Data With Informative Cluster Size
deletePharmaceutical Statistics
IF1.4
delete2026-03-01
delete0
PREAI
deleteSenevirathne, Hasika K. Wickrama; Dutta, Sandipan
deleteShare
deleteSave
Paired and AB/BA Cross-Over Design in Early Phase Clinical Trials: A Closer Look at Within-Subject Variance Bias
deletePharmaceutical Statistics
IF1.4
delete2026-03-01
delete0
PREAI
deleteWolfsegger, Martin J.; Xu, Peixin; Cotterill, Amy; Schutz, Helmut; Jaki, Thomas F.
deleteShare
deleteSave
New, Shorter Small-Sample Intervals for Vaccine Efficacy
deletePharmaceutical Statistics
IF1.4
delete2026-03-01
delete0
PREAI
deleteGasparini, Mauro; Di Trani, Vincenzo; Ratta, Marco
deleteShare
deleteSave